Ocugen, Inc. Logo

Ocugen, Inc.

Develops gene/cell therapies and vaccines, specializing in blindness and public health.

OCGN | NDAQ

Overview

Corporate Details

ISIN(s):
US43358V1098 (+1 more)
LEI:
Country:
United States of America
Address:
11 GREAT VALLEY PARKWAY, 19355 MALVERN
Sector:
Mining and quarrying
Industry:
Mining of non-ferrous metal ores

Description

Ocugen, Inc. is a clinical-stage biotechnology company focused on discovering, developing, and commercializing novel gene therapies, cell therapies, and vaccines. The company is a pioneer in developing treatments for blindness diseases, leveraging its breakthrough modifier gene therapy platform to address significant unmet medical needs in inherited retinal diseases. Ocugen's development pipeline also extends to vaccines and other biologics aimed at improving public health. The company operates with a patient-centric mission to deliver innovative therapeutic solutions for conditions with limited or no available treatment options.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Ocugen, Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Ocugen, Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Ocugen, Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
Xplus Inc. Logo
IT consultancy guiding digital transformation via enterprise architecture & program management.
South Korea 373200
XTL Biopharmaceuticals Ltd. Logo
Acquires and develops late-stage drugs for unmet medical needs, focusing on autoimmune diseases.
Israel XTLB
XTL BIOPHARMACEUTICALS LTD Logo
Acquires and develops late-stage drug candidates for treating autoimmune diseases.
United States of America XTLB
YAMADA Consulting Group  CO.,LTD. Logo
Japanese consulting firm offering global M&A, strategy, and financial advisory services.
Japan 4792
Y-Biologics, Inc Logo
Develops novel antibody cancer therapies using proprietary T-cell engager & antibody library tech.
South Korea 338840
Yellow Balloon Tour Co., Ltd. Logo
Offers domestic & international travel packages, flights, and tours for individuals and groups.
South Korea 104620
Yoshimura Food Holdings K.K. Logo
Acquires and revitalizes Japanese food SMEs via a support platform for global expansion.
Japan 2884
Ziccum AB Logo
Licenses ambient drying tech for pharma to create stable, cold-chain-free biologics.
Sweden ZICC
グロービング株式会社 Logo
Accelerates business growth via strategic consulting, AI implementation, and proprietary SaaS.
Japan 277A
株式会社D&Mカンパニー Logo
Optimizing healthcare & welfare businesses via finance, consulting, and HR solutions.
Japan 189A

Talk to a Data Expert

Have a question? We'll get back to you promptly.